GlucoTrack, Inc.

Lōkahi Therapeutics™ Expands University of Georgia Collaboration Through First International ai² Pipeline™ Project with Universität Paderborn

Lōkahi Therapeutics, a subsidiary of Glucotrack (Nasdaq: GCTK), launched its first international ai² Pipeline project pairing University of Georgia students with Universität Paderborn's garage33 to evaluate international therapeutic assets. The initiative expands the university network underpinning Lōkahi's fee-for-service model and is positioned to create revenue potential via sponsored projects and asset origination. No financial terms were disclosed; for a micro-cap like GCTK this is early-stage platform building rather than a near-term revenue event.

•1mo ago

Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14

Lōkahi Therapeutics, the subsidiary of Glucotrack (NASDAQ: GCTK), announced Qare, a comparative health platform for GLP-1 medications that lets users compare treatment experiences against similar patient cohorts. Qare becomes publicly available on October 14, 2026, launching in the GLP-1 category with additional drug classes expected to follow. CEO Erik Emerson framed the launch against a roughly $70 billion healthcare analytics market, arguing patients who generate the data do not benefit from it today. For GCTK this is an early-stage product introduction with no disclosed financials or adoption metrics; commercial traction remains the key watch item.

•1mo ago

Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform

Glucotrack subsidiary Lōkahi Therapeutics announced its first external fee-for-service engagement for the ai² PIPELINE platform, with nonprofit Innovate GBM sponsoring two project teams to identify brain tumor therapeutic assets. The deal marks the platform's transition from an internal discovery engine to a revenue-generating service model, supported by 14 existing university collaborations. Innovate GBM will independently decide whether to license any identified assets; Lōkahi positions the sponsor-led model as extensible to pharma, biotech, and investment organizations. No deal value was disclosed, and forward-looking statements flag capital-raising and platform-scaling risks.

•1mo ago

Lōkahi Therapeutics™ Expands ai² Into Three Opportunity-Creating Business Divisions

Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc., is expanding its ai² platform into three dedicated business divisions: ai² Pipeline™, ai² Talent™, and ai² Accelerator™. Since its launch one year ago, the platform has grown to include 13 universities and evaluated over 45 therapeutic assets, with several programs advancing into active business diligence. The new structure is designed to create multiple potential revenue streams, including strategic partnerships, licensing, and technology solutions, while continuing to advance Lōkahi's core pharmaceutical development strategy.

•1mo ago

Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of Business

Glucotrack's subsidiary Lōkahi Therapeutics added San Diego State University's Fowler College of Business to its ai² Futures Lab, a program that sources overlooked or deprioritized drug candidates through academic partnerships. In its first year the program engaged 64 students and identified more than 45 potential assets, several of which advanced into active pipeline discussions, which management called encouraging early validation of the model. SDSU participants will focus on therapeutic asset identification, evaluation, and strategic assessment, with recommendations that could feed partnership, licensing, or acquisition decisions — but the collaboration has no disclosed financial terms and no near-term revenue impact for GCTK.

•1mo ago

Lōkahi Therapeutics™ Initiates Clinical Trial Manufacturing for LT-100

Lōkahi Therapeutics, a subsidiary of Glucotrack, has initiated GMP manufacturing for LT-100, its honeybee venom-derived biologic candidate for osteoarthritis pain. The manufacturing campaign aims to support a new dosing regimen using a single subcutaneous injection, replacing the 15 intradermal injections used in prior efficacy trials. Pending successful manufacturing and regulatory review, the company expects to enroll the first patient later this year.

•2mo ago

Lōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Continued Collaboration with the University of Georgia

Lōkahi Therapeutics, a subsidiary of Glucotrack, expanded its ai² Futures Lab network by continuing its collaboration with the University of Georgia’s Student Industry Fellows Program. During its first year, the program engaged 64 students and identified over 45 potential acquisition assets, several of which advanced to active pipeline discussions. The initiative acts as a capital-efficient component of Lōkahi’s asset origination process, applying cross-functional expertise to real-world therapeutic opportunities.

•2mo ago

Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation

Glucotrack regained compliance with Nasdaq's stockholders' equity requirement and has been granted continued listing on the exchange by the Nasdaq Hearings Panel. CEO Erik Emerson stated the decision acknowledges substantial progress in repositioning the company and strengthening its financial foundation for long-term growth. The company currently operates through the Lōkahi Therapeutics biopharmaceutical platform and its Glucotrack Technologies subsidiary, which is developing a continuous blood glucose monitoring system.

•2mo ago

E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack

Lōkahi Therapeutics, a subsidiary of Glucotrack, secured $5.5 million in financing led by institutional investors. The capital raise consists of $2.0 million in equity priced at $0.75 per unit alongside a $3.5 million follow-on investment in convertible debt. Proceeds are intended to support the advancement of its therapeutic platform, with E.F. Hutton & Co. acting as exclusive financial advisor.

•2mo ago

Glucotrack Announces $5.5 Million Financing

Glucotrack secured approximately $5.5 million in gross proceeds from institutional investors, split between a $2.0 million equity financing and a $3.5 million follow-on investment in convertible debt. The equity units were priced at $0.75 per share, a premium to the market, and include five-year warrants exercisable at $1.50 per share. Management stated the capital strengthens the balance sheet and provides growth funding, highlighting the premium pricing as a strong signal of investor alignment.

•2mo ago

Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline

Lōkahi Therapeutics’ ai² Futures Lab identified more than 45 therapeutic opportunities on a budget of roughly $33,000 during its first year, representing over $500 million in prior industry investment. Five of these assets have advanced to active company discussions, featuring human clinical data and positive efficacy signals. The program is expanding from six to 12 university partners for the 2026-2027 academic year while achieving 100% retention of its inaugural partners. Student teams evaluate shelved or distressed assets through 8- to 10-week engagements, providing Glucotrack with a capital-efficient mechanism to source late-stage opportunities and expand its intelligence network.

•3mo ago

Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration

Lōkahi Therapeutics, a subsidiary of Glucotrack, announced progress in its LT-100 development strategy following a productive FDA Type C meeting and a successful nonclinical minipig study. The data supports transitioning the administration method from up to 15 intradermal injections to a single subcutaneous injection, with clinical evaluation planned to begin as early as Q4 2026. Management anticipates an initial readout from this single-injection approach during the first half of 2027.

•3mo ago

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing

Glucotrack entered a strategic business combination with Lōkahi Therapeutics, which will become the operating and controlling business while Glucotrack's existing CBGM operations continue as a wholly owned subsidiary. E.F. Hutton & Co. served as exclusive financial advisor for the merger and placement agent for approximately $5.7 million in convertible notes to fund post-closing growth.

•3mo ago

Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives

Glucotrack and its operating business Lōkahi Therapeutics completed a bridge financing to support the recently combined entity's strategic growth and integration efforts. E.F. Hutton & Co. served as exclusive financial advisor and placement agent for the transaction, continuing to support the company in evaluating future capital markets opportunities. The financing provides financial flexibility to advance the ai² platform and evaluate strategic opportunities within the biopharmaceutical development pipeline.

•3mo ago

Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform

Glucotrack received a Notice of Allowance from the USPTO for a patent application covering its implantable continuous blood glucose monitoring (CBGM) platform. The allowance adds to three patents issued in late 2025, expanding protection for the intravascular sensing lead and electronics assembly used in the fully implantable system. Management highlighted that strengthening the intellectual property portfolio is fundamental to the strategy as the device advances through clinical testing toward commercialization.

•3mo ago

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Glucotrack submitted an Investigational Device Exemption (IDE) application to the FDA to initiate a U.S. clinical study for its fully implantable continuous blood glucose monitor (CBGM). The company targets launching the U.S. clinical trial in the second half of 2026, supported by peer-reviewed data showing a 6.8% MARD and long-term sensor stability in preclinical models. Financially, Glucotrack reported a Q1 2026 net loss of $4.3 million and cash reserves of $3.9 million, with a runway extending into early Q3 2026. The company reduced debt by exchanging a portion of its promissory note for equity and drew $1.0 million on its equity line of credit.

•5mo ago

Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology

Glucotrack submitted an Investigational Device Exemption (IDE) application to the FDA to initiate a U.S. clinical study for its fully implantable continuous blood glucose monitoring (CBGM) technology. The submission marks progress from preclinical development toward clinical evaluation, aiming to provide a long-term, real-time, blood-based monitoring option without an on-body wearable. Management highlighted the device's 3-year sensor longevity and designed comfort, with plans to proceed with the study following FDA review.

•5mo ago

Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology

Glucotrack published a peer-reviewed study in the Journal of Diabetes Research demonstrating the long-term accuracy and stability of its implantable continuous blood glucose monitor in an ovine model. The study of 34 devices over up to 240 days showed a weighted average MARD of 6.8% with no device-related adverse safety events. These positive preclinical results support the company's advancement towards an FDA IDE submission and complement prior first-in-human data showing 7.7% MARD.

•6mo ago

Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology

Glucotrack published a peer-reviewed study in the IEEE Sensors Journal validating the year-long stability of its implantable glucose sensor technology. The findings represent the first year-long measurement of glucose oxidase enzyme decay, supporting the feasibility of the company’s target 3-year sensor lifespan. Management views the publication as a critical step toward submitting an Investigational Device Exemption (IDE) to the FDA.

•6mo ago